Clinical Trials

Aduro’s current clinical development programs are focused on potential treatments for a variety of cancers, including lung, prostate, metastatic colorectal and multiple myeloma cancers, as well as a variety of other solid tumors and lymphomas.

Concurrently, Aduro works with investigators at leading medical institutions to extend our development efforts through investigator-sponsored trials (ISTs).

Program

Indication

Trial Number

Trial Name

 STING Pathway Activator Programs

ADU-S100/MIW815 Multiple tumors NCT02675439 A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients with Advanced/Metastatic Solid Tumors or Lymphomas
ADU-S100/MIW815 Multiple tumors NCT03172936 A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection in Combination with PDR001, an investigational anti-PD-1 checkpoint inhibitor, to Patients With Advanced/Metastatic Solid Tumors or Lymphomas

 B-Select Program

Anti-April/BION-1301 Multiple Myeloma  NCT03340883 A Phase 1/2 Open-Label, Multicenter Study of the safety and efficacy of BION-1301 in patients with relapsed or refractory multiple myeloma.

 LADD® Programs

pLADD Colorectal Cancer NCT03189030 A Phase 1 Safety and Tolerability Study of Personalized Live, Attenuated, Double-Deleted Listeria Monocytogenes (pLADD) Immunotherapy in Adults With Metastatic Colorectal Cancer
ADU-741/JNJ-64041809 Prostate Cancer NCT02625857 An Open-Label, Phase 1 Study of the Safety and Immunogenicity of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Subjects with Metastatic Castration-resistant Prostate Cancer
ADU-214/JNJ-64041757 Lung Cancer NCT02592967 An Open Label Phase 1 Study of Safety and Immunogenicity of JNJ-64041757, A Live Attenuated Listeria Monocytogenes Immunotherapy, in Subjects with Non-Small Cell Lung Cancer

ADU-S100

Lead Candidate from the STING Pathway Activators Platform

Aduro is developing ADU-S100, a novel synthetic molecule that activates human STING (Stimulator of INterferon Genes), in collaboration with Novartis. ADU-S100 is being evaluated in a Phase 1 clinical trial in cutaneously-accessible tumors, including breast, head-and-neck, and renal cell cancers as well as lymphoma and melanoma. The trial is evaluating the ability of ADU-S100 to activate the immune system and recruit specialized immune cells to attack the injected tumor as well as distant metastases.

BION-1301

Lead Candidate from the B-select Platform

BION-1301 is Aduro’s proprietary monoclonal antibody targeting APRIL, which the company is evaluating in patients with multiple myeloma. Preclinical studies demonstrated that BION-1301 halts tumor growth, overcomes drug resistance to standard-of-care agents such as lenalidomide and bortezomib, and relieves immunosuppression. BION-1301 is currently being evaluated in a Phase 1/2 clinical trial.